Mobocertinib (Exkivity)

mobocertinib · Takeda Pharmaceutical Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Mobocertinib (Exkivity), covering 2023-10-03 to 2023-10-03. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer [Phase 1]